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Comparison of Humoral and Cellular Immune Responses to Inactivated
Swine Influenza Virus Vaccine in Weaned Pigs
Abstract
Humoral and cellular immune responses to inactivated swine influenza virus (SIV) vaccine were evaluated
and compared. Fifty 3-week-old weaned pigs were randomly divided into the non-vaccinated control group
and vaccinated group containing 25 pigs each. Pigs were vaccinated intramuscularly twice with adjuvanted
UV-inactivated A/SW/MN/02011/08 (MN/08) H1N2 SIV vaccine at 6 and 9 weeks of age. Whole blood
samples for multi-parameter flow cytometry (MP-FCM) and serum samples for hemagglutination inhibition
(HI) assay were collected at 23 and 28 days after the second vaccination, respectively. A standard HI assay and
MP-FCM were performed against UV-inactivated homologous MN/08 and heterologous pandemic A/CA/
04/2009 (CA/09) H1N1 viruses. While the HI assay detected humoral responses only to the MN/08 virus,
the MP-FCM detected strong cellular responses against the MN/08 virus and significant heterologous
responses to the CA/09 virus, especially in the CD4+CD8+ T cell subset. The cellular heterologous responses
to UV-inactivated virus by MP-FCM suggested that the assay was sensitive and potentially detected a wider
range of antigens than what was detected by the HI assay. Overall, the adjuvanted UV-inactivated A/SW/
MN/02011/08 H1N2 SIV vaccine stimulated both humoral and cellular immune responses including the
CD4−CD8+ T cell subset.
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a  b  s  t  r  a  c  t
Humoral  and  cellular  immune  responses  to  inactivated  swine  inﬂuenza  virus  (SIV)  vaccine
were  evaluated  and  compared.  Fifty  3-week-old  weaned  pigs  were  randomly  divided  into
the  non-vaccinated  control  group  and  vaccinated  group  containing  25 pigs  each.  Pigs  were
vaccinated  intramuscularly  twice  with  adjuvanted  UV-inactivated  A/SW/MN/02011/08
(MN/08)  H1N2  SIV  vaccine  at 6  and  9 weeks  of  age.  Whole  blood  samples  for  multi-
parameter  ﬂow  cytometry  (MP-FCM)  and  serum  samples  for  hemagglutination  inhibition
(HI)  assay  were  collected  at 23  and  28  days  after  the  second  vaccination,  respectively.  A  stan-
dard HI  assay  and  MP-FCM  were  performed  against  UV-inactivated  homologous  MN/08  and
heterologous  pandemic  A/CA/04/2009  (CA/09)  H1N1  viruses.  While  the HI  assay  detected
humoral  responses  only  to  the  MN/08  virus,  the  MP-FCM  detected  strong  cellular  responses
against  the  MN/08  virus  and  signiﬁcant  heterologous  responses  to  the CA/09  virus,  espe-
cially  in the  CD4+CD8+  T cell subset.  The  cellular  heterologous  responses  to UV-inactivated
virus  by MP-FCM  suggested  that  the  assay  was  sensitive  and  potentially  detected  a wider
range of  antigens  than  what  was  detected  by the  HI  assay.  Overall,  the  adjuvanted  UV-
inactivated  A/SW/MN/02011/08  H1N2  SIV  vaccine  stimulated  both  humoral  and  cellular
immune  responses  including  the  CD4−CD8+  T  cell subset.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Swine inﬂuenza virus (SIV) is a negative strand, seg-
mented, enveloped RNA virus of the Orthomyxoviridae
family. Inﬂuenza infection in swine is recognized clin-
ically as an acute respiratory disease characterized by
fever, coughing, lethargy, anorexia and nasal discharge
(McQueen et al., 1968; Alexander and Brown, 2000; Richt
et al., 2003). Over the past ten years, vaccinating against SIV
∗ Corresponding author.
E-mail address: jaroth@iastate.edu (J.A. Roth).
1 Current address: College of Agronomy and Veterinary Medicine, Uni-
versity of Passo Fundo, RS, Brazil.
has become a common practice in the US swine industry.
However, the development of efﬁcacious, cross-reactive
vaccines has been challenged by the rapid change in SIV
subtypes due to reassortment and antigenic drift. Inac-
tivated vaccines, commercially available in the US since
1994, have been shown to play a signiﬁcant role in pre-
venting SIV infection through the generation of anti-SIV
antibodies (Bikour et al., 1996). In addition, hemaggluti-
nation inhibition (HI) antibody titers in the serum have
been used to predict clinical protection against challenge
virus. However, HI titers against homologous virus may
provide only partial protection against heterologous chal-
lenge (Vincent et al., 2008).
Protective immunity against infection with inﬂuenza
involves both the humoral and cell-mediated immune
0165-2427/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
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(CMI) response. Many studies investigating the immune
response to inﬂuenza virus have been conducted in mice.
Collectively, these studies have shown that a combina-
tion of neutralizing antibodies, mucosal immune responses
and T cells are important for protection and recovery
from disease (Tamura et al., 2005). Cell-mediated immune
responses that include CD4+ T helper cells and CD8+ cyto-
toxic T cells have also been shown to be important for
protection or recovery against heterosubtypic challenge in
mice, respectively (Liew et al., 1984; Moran et al., 1999;
Nguyen et al., 1999, 2001). In addition, IgA has been shown
to be more cross-reactive against heterologous challenge
than IgG in mice (Tamura et al., 1991). Although reports
describing the immune response to inﬂuenza vaccines or
infection are limited in the swine host; humoral immune
responses that include both IgA and IgG at the mucosal
level have been shown to be important for protecting the
respiratory tract from SIV in swine (Larsen et al., 2000).
Future control of inﬂuenza A viruses in swine will
depend on the development and use of vaccines that
provide adequate cross-protection and the induction of
an immune response based on both humoral and cell-
mediated mechanisms. Collectively, inﬂuenza studies in
a natural host, such as swine, are limited and minimal
information regarding the humoral and CMI responses
elicited by inactivated vaccines are available. The objec-
tives of this study were to evaluate and compare the
humoral and cellular responses to homologous and het-
erologous viruses following inactivated SIV vaccination,
using standard HI assays and multi-parameter ﬂow cytom-
etry (MP-FCM). The MP-FCM has been well established
in our laboratory to measure speciﬁc CMI  responses to
viral and bacterial antigens in bovine, porcine, and equine
systems using 4–6 color combinations (Charerntantanakul
et al., 2006a, 2006b; Platt et al., 2008, 2009, 2010a,
2010b). This study reports our current porcine 6-color
MP-FCM.
2. Materials and methods
2.1. Experimental animals and vaccine
Fifty 3-week-old pigs from a herd free of SIV and
PRRSV were used in the study. These pigs were part of
the study of Gauger et al. (submitted for publication).
Pigs were screened for inﬂuenza A nucleoprotein antibody
by ELISA (Multi-S ELISA, IDEXX Laboratories, Inc., West-
brook, ME)  prior to the study to ensure the absence of
SIV speciﬁc antibody. To reduce confounding effects of
respiratory tract bacterial co-infections, pigs were treated
with ceftiofur crystalline free acid (Pﬁzer Inc., New York,
NY) at three weeks and tulathromycin injectable solution
(Pﬁzer Inc., New York, NY) at 8 days before ﬁrst vacci-
nation according to manufacturer recommendations. The
pigs were randomly divided into two groups. Pigs in the
control group (n = 25) were not vaccinated. Pigs in the
vaccinated group (n = 25) were inoculated intramuscularly
with 2 ml  UV-inactivated A/SW/MN/02011/08 H1N2 SIV
vaccine (105.7 TCID50/ml) with an emulsiﬁed oil-in-water
adjuvant (Emulsigen®-D, MVP  Technologies, Omaha, NE) at
6 and 9 weeks of age. The pigs were housed at the National
Animal Disease Center (NADC) and cared for in compliance
with the Institutional Animal Care and Use Committee.
2.2. Recall antigens
The homologous vaccine strain A/SW/MN/02011/2008
H1N2 (MN/08) (a -cluster H1 SIV) and the heterologous
pandemic A/CA/04/2009 H1N1 (CA/09) (a 2009 pandemic
H1 SIV) were propagated in MDCK cells to approximately
105.7 TCID50/ml. The viruses in media were inactivated
using the sterilize setting in an ultraviolet cross-linking
chamber (GS Gene Linker, Bio-Rad, Hercules, CA). Culture
media supernatant from uninfected MDCK cells served as
mock antigen.
2.3. Blood samples
Whole blood samples were collected 23 days after
second vaccination in vacutainer cell preparation tubes
with sodium citrate (CPTTM, cat # 362761, BD Diagnos-
tics, Franklin Lakes, NJ). The peripheral blood mononuclear
cells (PBMC) were isolated within 2 h of collection and
activated within the same day. Serum samples were sep-
arated from blood collected into serum separator tubes
on day 28 after second vaccination and utilized in the
HI assay.
2.4. Hemagglutination inhibition assay
Sera used in the HI assay were heat-inactivated at 56 ◦C
for 30 min. Non-speciﬁc HA inhibitors were removed with a
20% suspension of kaolin (Sigma Aldrich, St. Louis, MO,  USA)
and natural serum agglutinins were removed by adsorp-
tion with 0.5% turkey red blood cells (RBCs). The HI assay
was performed against the homologous MN/08 and het-
erologous CA/09 viruses with turkey RBC using standard
techniques (Palmer et al., 1975). Reciprocal titers for HI
assays were log2 transformed for statistical analysis and
reported as geometric means.
2.5. Multi-parameter ﬂow cytometry
2.5.1. Peripheral blood mononuclear cell isolation
The CPT tubes were centrifuged at 1500 × g for 30 min
at room temperature (∼25 ◦C) within 2 h after blood col-
lection. The PBMC (2–3 ml)  were collected into 15 ml
conical centrifuge tubes. The red blood cells were lysed
with 6 ml  buffered water (deionized water with 0.15 M
Na2HPO4 and 0.15 M KH2PO4) for 90 s followed by 3 ml
of 3× PBS. The tubes were centrifuged at 700 × g for
10 min  and the PBMC were washed in 10 ml  PBS. After cen-
trifugation, the PBMC were resuspended in 3 ml  RPMI++
(RPMI 1640 (Mediatech, Inc., Herndon, VA) with 15% fetal
bovine serum (Atlanta Biologicals, Norcross, GA), 1.5% peni-
cillin/streptomycin/amphotericin B solution (Mediatech,
Inc., Herndon, VA) and 1.5 g/ml gentamicin (Gibco, Invit-
rogen Co., Grand Island, NY)). The PBMC suspensions were
counted and 107 cells of each sample were diluted with
RPMI++ to 2 ml  (5 × 106 cells/ml) in new tubes.
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2.5.2. PBMC activation
PBMC were activated in 96-well ﬂat-bottomed tissue
culture microtiter plates (Falcon, BD Labware, Franklin
Lakes, NJ), 7 wells for each sample. One well received 50 l
RPMI++ as non-antigen stimulation control. The second
well received 50 l ConA at 5 g/ml ﬁnal concentration as
mitogen control. The third well received 50 l undiluted
MDCK media and served as the mock-stimulation con-
trol. Each strain of undiluted UV-inactivated SIV was added
to duplicate wells as SIV-stimulation wells. Two hundred
microliters of each PBMC suspension with 106 cells were
added to each of 7 wells and the plates were incubated in
a 5% CO2 humidiﬁed incubator at 37 ◦C.
2.5.3. PBMC staining
Four days after activation, in order to block protein
transport, brefeldin A (50 l) (BD Biosciences Pharmingen,
San Diego, CA) was added to 96-well round-bottomed tis-
sue culture microtiter plates (Falcon, BD Labware, Franklin
Lakes, NJ) at the concentration recommended by the man-
ufacturer, in the same pattern as the PBMC activation
plates. The PBMC were then transferred correspondingly
and mixed well with brefeldin A. The plates were incubated
for an additional 4 h.
Plates were then centrifuged at 430 × g for 1 min  and the
supernatants removed by a ﬁrm rapid ﬂicking of the plates.
The PBMC were washed once with 100 l PBS++ (PBS with
0.5% bovine serum albumin, and 0.1% sodium azide). All
washing steps and antibody removal from the plates were
by the same centrifugation and plate ﬂicking cycle. All anti-
bodies used in the staining were previously titrated for
their optimum concentrations in the same PBMC setting
(data not shown). The primary antibody mix  for surface
antigens (50 l) was added to all PBMC wells except the
secondary antibody control wells and incubated at room
temperature (RT, 25 ◦C) for 15 min. The mAb  mix  consisted
of mouse anti-swine CD4 (IgG2b, cat# 74-12-4, VMRD, Inc.,
Pullman, WA), mouse anti-swine CD8 (IgG2a, cat# 76-
2-11, VMRD, Inc., Pullman, WA), rat anti-swine  TCR
(Rat IgG2a, cat# 551543, BD Pharmingen, San Diego, CA),
mouse anti-swine CD25 (IgG1, cat# PGBL25A, VMRD, Inc.,
Pullman, WA)  in PBS++. The primary antibody mix  was
removed after incubation and the cells were washed twice
with 100 l PBS++. The secondary antibody mix  for sur-
face antigens (50 l) was  added to all PBMC wells including
the secondary antibody control wells and incubated at
room temperature for 15 min. The secondary antibody mix
consisted of goat anti-mouse IgG2b-AF647 (Alexa Fluor
647, cat# A21242, Invitrogen, Carlsbud, CA), goat anti-
mouse IgG2a-PE (Phycoerythrin, cat# P21139, Invitrogen,
Carlsbud, CA), goat anti-rat IgG2a-FITC (cat# STAR113F,
AbDSerotec, Raleigh, NC), and goat anti-mouse IgG1-PE-
TR (Phycoerythrin-Texas Red, cat# M32017, Invitrogen,
Carlsbud, CA) in PBS++. The secondary antibody mix was
removed after incubation and the cells were washed three
times with 100 l PBS++. For intracellular staining, the
PBMC were treated with 100 l BD cytoﬁx-cytoperm solu-
tion (BD Biosciences Pharmingen, San Diego, CA) at RT for
30 min  and washed once with BD perm-wash solution (BD
Pharmingen, San Diego, CA). The intracellular primary anti-
body mix, consisted of rabbit anti-swine IFN- (polyclonal
antibody, cat# ASC4032, Invitrogen, Carlsbud, CA) and
mouse anti-swine IL-10-biotin (IgG1, cat# ASC9109, Invit-
rogen, Carlsbud, CA), in BD perm-wash solution (50 l),
was  added to all wells except the secondary antibody con-
trol wells and incubated at RT for 15 min. The intracellular
primary antibody mix  was  removed after incubation and
cells were washed twice with 100 l BD perm-wash solu-
tion. The goat anti-rabbit IgG-AF700 (Alexa Fluor 700, cat#
A21038, Invitrogen, Carlsbud, CA) and streptavidin-PerCP-
Cy5.5 (cat#551419, BD Pharmingen, San Diego, CA) (50 l)
in BD perm-wash solution was  added to all wells includ-
ing the secondary antibody control wells and incubated
at RT for 15 min. The cells were washed three times with
100 l BD perm-wash solution. Ultrapure formaldehyde
(Polyscience, Warrington, PA) 1% solution in PBS (250 l)
was  added to all wells and the cells were transferred to ﬂow
tubes (Falcon cat # 352008, BD Labware, Franklin Lakes, NJ)
and kept in the dark at 4 ◦C until ﬂow cytometry analysis.
The samples were analyzed by the Flow Cytometry Facility,
Ofﬁce of Biotechnology, Iowa State University using FAC-
SCanto cytometer (BD Biosciences, San Jose, CA). Data were
collected from at least 10,000 live cells of each sample.
2.5.4. Flow analysis
FlowJo cell analysis software (Tree Star Inc., Ashland,
OR) was used to analyze FCM data. From the total PBMC
population, T cell subsets were identiﬁed based on the
combination of CD4, CD8 and  TCR expression or lack
thereof. The CD4+, CD4+CD8+ (double positive), CD8+, +
T cells and non T cells (PBMC with no T cell markers) were
refer to CD4+CD8−−,  CD4+CD8+−,  CD4−CD8+−,
CD4−CD8−+ and CD4−CD8−−, respectively.
Gates for expression of CD25+, IFN-+ and IL-10+ were
set using the non-antigen-stimulated (media only) sample
for each T cell subset for each individual pig. The same gates
for each parameter of each subset for each pig were applied
to the mock and SIV-stimulated samples of the same sub-
set of the same pig. The increase in % positive cells for each
parameter was  calculated by subtracting % positive cells
of non-antigen-stimulated samples from % positive cells of
mock-stimulated samples and of SIV-stimulated samples
(the average of duplicate wells was  used). The net per-
centage increase was  obtained by subtracting the increase
of % positive cells of mock-stimulated samples from the
increase of % positive cells of SIV-stimulated samples of the
same pig. Samples that yielded a net percentage less than
0 were adjusted to 0 before statistical analysis.
2.5.5. Statistical analysis
Statistical analysis program JMP  8 (SAS Institute Inc.,
Cary, NC) software was  used to analyze ﬂow data. The sig-
niﬁcant differences between control and vaccinated groups
were evaluated using t-test or pooled t-test according to
their analysis of variances. A probability of p < 0.05 was
considered statistically signiﬁcant.
3. Results and discussion
Vaccinated pigs demonstrated homologous HI titers
ranging from 10 to 160 with a geometric mean ± standard
error of the mean of 36 ± 12. There was  no detectable
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Fig. 1. Comparison of net increases in % positive T cell subset responses for CD25, IFN- and IL-10 between control (C) and vaccinated (V) groups against UV-
inactivated homologous MN/08 and heterologous CA/09 viruses (CD4: CD4+CD8−−, CD4+CD8: CD4+CD8+−, CD8: CD4−CD8+−, : CD4−CD8−+,
Non  T: CD4−CD8−− cells). Signiﬁcantly different from control group *p < 0.05, **p < 0.01.
cross-reactivity with heterologous virus. Non-vaccinated
control pigs did not develop an HI antibody response to
either antigen. The HI results are summarized in Table 1.
Humoral responses to SIV vaccines and natural infection
have been studied by HI assay (Larsen et al., 2000; Richt
et al., 2006; Wesley and Lager, 2006; Van Reeth et al., 2006;
Li et al., 2009), ELISA (Larsen et al., 2000; Richt et al., 2006;
Li et al., 2009), isotype-speciﬁc antibody secreting cell
ELISPOT assays (Larsen et al., 2000), Western immunoblot
Table 1
Serum geometric mean HI titers ± standard errors of mean against UV-
inactivated homologous MN/08 and heterologous CA/09 viruses.
Antigen Group
Control Vaccinated
Homologous MN/08 0.0 ± 0.0 36 ± 12**
Heterologous CA/09 0.0 ± 0.0 0.0 ± 0.0
** Signiﬁcantly higher than control group and heterologous antigen,
p  < 0.01.
(Kim et al., 2006) and virus neutralization (VN) tests (Van
Reeth et al., 2006; Li et al., 2009). The HI is by far the most
commonly used assay. In this study, there was no cross
HI reaction between heterologous SIV strains as expected
with divergent HA observed between MN/08 and CA/09.
Indeed, of the viral structural and non-structural genes, the
identity ranged from 91 to 94% for the polymerase genes
and 95% for NP and NS, whereas the HA demonstrated only
77% identity. The NA and M genes were of lower identity as
well due to the divergence in subtype and genetic lineage,
respectively.
Mean net increases of CD25+, IFN-+, and IL-10+ in
PBMC and T cell subsets in response to SIV stimulation are
compared in Fig. 1. Pigs vaccinated with inactivated whole
virus with adjuvant had signiﬁcantly higher net %CD25+
in all T cell subsets with the exception of + T cells in
response to homologous recall antigen. In contrast, PBMC
from vaccinated pigs cross-reacted to heterologous recall
antigen only in the CD4+CD8+ subset. The net %IFN-+
responses of the vaccinated pigs were signiﬁcantly higher
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than the control group in CD4+CD8+ and CD8+ for both
homologous and heterologous recall antigens. Interest-
ingly, the net %IL-10+ responses of the vaccinated pigs
were signiﬁcantly lower than the control group in the CD4+
subset against homologous antigen and the non T cells of
both antigens, while the CD4+CD8+ subset had signiﬁcantly
higher net %IL-10+ responses to both antigens. There were
no signiﬁcant changes in the expression of CD25, IFN-
or IL-10 in the + population between control pigs and
vaccinated pigs after restimulation with either virus type.
Cellular responses to SIV have been less commonly
reported and studied only by T cell proliferation (Kitikoon
et al., 2006, 2009a, 2009b)  and IFN- ELISPOT assays
(Larsen et al., 2000). A report in pigs showed a signiﬁcant
increase in SIV speciﬁc CD4+CD8+ proliferation, but no sig-
niﬁcant changes in other T cell subsets, when stimulated
with either the homologous or heterologous inactivated
viruses (Kitikoon et al., 2006). The authors concluded that
the vaccine was able to induce a systemic SIV-speciﬁc
memory T cell response. We  observed similar results
by MP-FCM in that the inactivated vaccine could prime
the CD4+CD8+ T cell subset, a population of T cells that
have been demonstrated to be memory T cells in swine
(Zuckermann and Husmann, 1996; Charerntantanakul and
Roth, 2007). Although we did not measure antigen-speciﬁc
proliferation, which is often used for evaluating antigen-
speciﬁc recall responses, we did evaluate changes in
expression of intracellular IFN- (Th1 cytokine) and IL-10
(Th2 cytokine), both of which are produced in response to
speciﬁc recall antigens. In addition, we evaluated antigen-
speciﬁc changes in the expression of CD25, the high afﬁnity
 chain of the IL-2 receptor present on activated T cells
on each T cell subset. The MP-FCM results from our study
detected increased expression of all 3 parameters in the
CD4+CD8+ T cell of vaccinated pigs in response to both
heterologous and homologous recall antigens. In addition,
our results showed a decrease in IL-10+ cells in CD4+ T
cells and non T cells. The decrease in IL-10+ CD4+T cells
was only signiﬁcant in response to homologous antigen.
Without examining T cell subset identiﬁcation, the results
from total PBMC would indicate a reduction in overall IL-10
expression. Thus, T cell subset identiﬁcation is important
when evaluating the percentage of cells producing cytokine
in response to recall antigen. The reason for the decrease
in IL-10+ T cell subsets is unknown. IFN- has been shown
to inhibit Th2 cytokine production (Chomarat et al., 1993).
These data suggest that IFN- may  inhibit IL-10 produc-
tion in CD4+ T cells and non T cells, but not in CD4+CD8+ T
cells in pigs. According to porcine T cell subset phenotypes
described by Gerner et al. (2009),  the CD8+ T cell phenotype
in this study includes natural killer (NK) cells which may
explain the ability of the inactivated vaccine to prime the
CD8+ T cells as evidenced by a signiﬁcant increase in the
percentage of IFN-+ cells in response to both recall anti-
gens. A combination of IL-12 and IL-18 has been shown to
stimulate NK cells for enhanced IFN- production (Gerner
et al., 2009). Perhaps these cytokines produced by CD4+ T
cells stimulated IFN- production by CD8+ NK cells. On the
other hand, the UV-inactivated recall viruses used in this
study may  be able to enter the cells and uncoat in the cyto-
plasm. The translation mechanism may  not be completely
blocked. In this case, it is possible that the translated viral
antigens are presented on MHC  I to CD8+ T cells. There is
also the possibility of cross-presentation of viral proteins
contained in the vaccine preparation onto MHC  I through
the exogenous pathway (Murphy et al., 2007).
The A/SW/MN/02011/08 H1N2 SIV vaccine used in this
study was demonstrated to effectively prime both humoral
and cellular immune responses. However, cross reactiv-
ity to the UV-inactivated heterologous pandemic H1N1
CA/09 recall virus was  observed in cellular but not in
the HI humoral responses. The cellular cross reactivity
to UV-inactivated heterologous virus measured by the
MP-FCM suggests that the assay is sensitive and likely
detects a wider range of viral epitopes than the HI assay.
This suggests that inactivated SIV vaccines may provide
some protection against heterologous infection, even when
cross-reactivity is not observed in the HI assay. It will be
important to characterize the homologous and heterolo-
gous T cell subset responses using live recall viruses to gain
a more complete understanding.
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